Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Operating Expenses (2016 - 2025)

Fate Therapeutics' Operating Expenses history spans 14 years, with the latest figure at $36.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 43.26% year-over-year to $36.1 million; the TTM value through Dec 2025 reached $154.4 million, down 31.07%, while the annual FY2025 figure was $154.4 million, 31.07% down from the prior year.
  • Operating Expenses reached $36.1 million in Q4 2025 per FATE's latest filing, down from $36.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $108.8 million in Q4 2022 to a low of $36.1 million in Q4 2025.
  • Average Operating Expenses over 5 years is $65.5 million, with a median of $58.8 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: surged 76.33% in 2021, then crashed 54.26% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $86.5 million in 2021, then increased by 25.82% to $108.8 million in 2022, then plummeted by 54.26% to $49.8 million in 2023, then rose by 27.85% to $63.6 million in 2024, then crashed by 43.26% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Operating Expenses are $36.1 million (Q4 2025), $36.5 million (Q3 2025), and $38.9 million (Q2 2025).